Phase 1 Study Evaluating Safety of Trastuzumab Deruxtecan with Immunotherapy and Chemotherapy in Advanced or Metastatic HER2-Positive Non-Squamous Non-Small Cell Lung Cancer
Led by AstraZeneca · Updated on 2026-04-13
304
Participants Needed
91
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of trastuzumab deruxtecan T-DXd combined with immunotherapy agents, with or without chemotherapy, in patients who have HER2 over-expressing non-small cell lung cancer NSCLC. This phase Ib study focuses on advanced or metastatic non-squamous NSCLC patients, aiming to understand optimal dosing and safety profiles. The study is sponsored by AstraZeneca and includes multiple study parts to explore different drug combinations and regimens.
The trial includes several parts Part 1 involved dose escalation of T-DXd with durvalumab plus cisplatin, carboplatin, or pemetrexed Parts 3, 4, and 5 assess combinations of T-DXd with volrustomig or rilvegostomig, with or without carboplatin, in various dosing schedules. Patients receive the study drugs as intravenous infusions. Some parts involve randomization between arms with or without carboplatin, focusing on dose optimization in first-line treatment settings. Enrollment in some parts is closed, while others continue to explore safety and efficacy.
Participants undergo regular assessments including tumor measurements by RECIST 1.1, organ and bone marrow function tests, and monitoring of adverse events for about 20 months. The study measures safety outcomes like frequency of adverse events and serious adverse events, and secondary outcomes such as response rate, duration of response, disease control, progression-free survival, overall survival, and pharmacokinetics of the drugs. Immunogenicity of the treatments is also evaluated. Participants must have measurable disease and meet performance status criteria, with follow-up to assess treatment effects and safety.
CONDITIONS
Brief Title
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Research Team
A
AstraZeneca Clinical Study Information Center
A
AstraZeneca Lung Cancer Study Locator Service
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
T‑DXd‑Based Regimens
Pembrolizumab + Platinum‑Chemo
What it is
Experimental regimens using trastuzumab deruxtecan combined with durvalumab and various chemotherapy agents, volrustomig or rilvegostomig, or T‑DXd alone, evaluated in multiple parallel arms of the Phase Ib study.
The established first‑line treatment for HER2‑mutant advanced NSCLC is pembrolizumab plus platinum‑based chemotherapy.
Role in trial
These are the investigational arms being tested for safety and tolerability in treatment of HER2‑OE NSCLC.
Not part of this trial; used as external clinical reference for first‑line care.
Primary use
Being studied as first‑line therapy options for advanced or metastatic HER2‑OE NSCLC.
Current standard first‑line therapy combining immunotherapy with platinum‑based chemotherapy for similar patients.
How it is given or performed
Administered as combination intravenous infusions, varying by arm (T‑DXd with durvalumab and/or platinum agents, volrustomig, rilvegostomig).
Delivered as intravenous infusion of pembrolizumab plus platinum‑based chemotherapy.
Evidence status
Safety and tolerability are being assessed; efficacy signals are exploratory at this stage.
Well‑established efficacy in general NSCLC first‑line setting, though data are not specific to HER2‑mutant NSCLC.
Important risks
Safety profile under evaluation; not yet fully characterized.
Safety risks include known toxicities from immunotherapy and platinum‑based chemotherapy.
Important limitations
Early‑phase single‑arm study with multiple regimen variations; efficacy and safety not yet confirmed compared with standard care.
Efficacy data mostly from general NSCLC; may not apply directly to HER2‑mutant or overexpressing subgroups.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Histologically confirmed unresectable locally advanced or metastatic non-squamous non-small cell lung cancer
Progression after 1 or 2 lines of systemic therapy for Part 1; treatment-nafve for advanced/metastatic disease in Parts 3, 4, and 5
Tumors must not have known genomic alterations or actionable driver kinases with approved therapies for Parts 3, 4, and 5
HER2 overexpression confirmed by central tumor tissue review
ECOG performance status of 0 or 1
Measurable disease by RECIST 1.1
Adequate organ and bone marrow function as defined by protocol
Minimum body weight of 35 kg for Parts 3, 4, and 5
You will not qualify if you...
Known HER2 mutation
History of non-infectious interstitial lung disease or pneumonitis requiring steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis not ruled out by imaging
Lung-specific serious illnesses including prior pneumonectomy
Active primary immunodeficiency, known HIV infection, active or unresolved hepatitis B or hepatitis C infection
Active infection requiring intravenous antibiotics, antivirals, or antifungals
Untreated or symptomatic central nervous system metastases requiring corticosteroids or anticonvulsants
Ascites or pericardial effusion needing drainage or shunts
Active non-infectious skin diseases requiring systemic treatment or autoimmune/inflammatory disorders needing chronic immunosuppressive therapy
Unresolved toxicities above Grade 1 from previous anticancer therapy
Contraindications to platinum-based chemotherapy
Prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT, or other experimental immunotherapies
History of substance abuse or other medical/psychological conditions interfering with study participation
History of thromboembolic events within 3 months before first dose (including pulmonary embolism, deep vein thrombosis, cerebral venous sinus thrombosis)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 20 months
Participants receive treatment with combinations of T-DXd and immunotherapy agents, with or without chemotherapy, administered as IV infusions. Treatment includes various drug combinations such as T-DXd with durvalumab and cisplatin or carboplatin, or T-DXd with volrustomig or rilvegostomig, with or without carboplatin, depending on the assigned arm.
Regular visits for treatment and monitoring (frequency determined by protocol)
Follow-up
Duration - Up to 20 months
Participants are monitored for safety, tolerability, and treatment response after completion of treatment. This includes assessments of adverse events, response rate, progression-free survival, overall survival, pharmacokinetics, and immunogenicity.
Scheduled visits for safety and efficacy assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
10
Similar Trials
Study of XZP-5955 Tablets for Adults With NTRK or ROS1 Fusion Positive Advanced or Metastatic Solid Tumors
Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets in Adults with Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1 Study Evaluating Safety of Trastuzumab Deruxtecan with Immunotherapy and Chemotherapy in Advanced or Metastatic HER2-Positive Non-Squamous Non-Small Cell Lung Cancer
Phase II Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments for Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Dose Escalation and Expansion Study Evaluating Safety and Activity of PF-07248144 Alone and in Combination for Advanced or Metastatic Solid Tumors